103 CARNEGIE CENTER, PRINCETON, NJ
Investor Presentation
Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for the Treatment of Patients with aSAH
Consulting Agreement with Ms. D'Andrea Following Departure
Provides Regulatory Update on New Drug Application for GTx-104
Announces Third Quarter 2026 Financial Results, Provides Business Update
News, Material Contracts
Announces Second Quarter 2026 Financial Results, Provides Business Update
FY 2025
Q3
Amended Quarterly Report
Q2
Q1
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS